| Entry |
|
|---|
| Name |
Mutation-activated PI3K to PI3K signaling pathway
|
|---|
| Definition |
PI3K* -> PIP3 -> AKT -> MTOR -> S6K |
|---|
| Expanded |
5290v1 -> C05981 -> (207,208,10000) -> 2475 -> (6198,6199) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00048 | Hepatocellular carcinoma |
|
|---|
| Gene |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 2475 | MTOR; mechanistic target of rapamycin |
| 6198 | RPS6KB1; ribosomal protein S6 kinase B1 |
| 6199 | RPS6KB2; ribosomal protein S6 kinase B2 |
|
|---|
| Variant |
5290v1 (PI3K*) PIK3CA mutation
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Ignatiadis M, Sotiriou C |
|---|
| Title |
Luminal breast cancer: from biology to treatment. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Mukohara T |
|---|
| Title |
PI3K mutations in breast cancer: prognostic and therapeutic implications. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Whittaker S, Marais R, Zhu AX |
|---|
| Title |
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
